Molecular data
| Physical form | Lyophilized powder blend |
|---|---|
| Available sizes | 20mg |
How it works
Angiogenesis & Cytoprotection
Raised VEGF expression and new vessel formation have been measured for BPC-157, alongside perfusion of the surrounding tissue. NO system activity and cytoprotective endpoints are also characterised.
- VEGF-mediated angiogenesis
- Nitric oxide system modulation
- Gastric and tissue cytoprotection
Cell Migration & Actin Regulation
TB-500 sequesters G-actin monomers, with cytoskeletal remodelling and cell migration toward injury sites measured. Integrin-linked kinase (ILK) signalling is also characterised.
- Actin-mediated cell migration
- Integrin-linked kinase activation
- Anti-fibrotic remodeling
Complementary Pathways
BPC-157 is characterised on vascular endpoints (perfusion at the injury site), TB-500 on cell mobilisation to the same site. The two cover distinct pathways — perfusion and cellular migration.
- Perfusion endpoints (BPC-157)
- Phase 2: Cell mobilization (TB-500)
- Combined anti-inflammatory effects
What the research shows
Tendon & Ligament
BPC-157 is studied in tendon models while TB-500 is characterised for cell migration toward the injury site; the pairing is investigated as a combined condition.
Wound Closure Models
TB-500 is studied in dermal and scarring models; BPC-157 for vascular endpoints including perfusion at wound sites.
Vascular Models
Angiogenesis via the NO system is measured for BPC-157; cardiac cell migration through ILK activation for TB-500.
Inflammatory Signalling
Anti-inflammatory endpoints are measured for both peptides through distinct mechanisms.
Specification
| Components | BPC-157 + TB-500 (Thymosin Beta-4) |
|---|---|
| BPC-157 Sequence | 15 amino acids (Gly-Glu-Pro-Pro-Pro...) |
| TB-500 Fragment | 43-amino acid active region of Tβ4 |
| Form | Lyophilized powder blend |
| Purity | ≥99% per component (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
| Strength | 20mg |
| Purity (HPLC) | >99% (HPLC) |
| Appearance | White to off-white powder |
| Stability | 24 months from manufacture date when stored properly |
Frequently asked questions
Why combine BPC-157 and TB-500?
BPC-157 and TB-500 act through complementary mechanisms. Vessel formation (angiogenesis) and perfusion are measured for BPC-157; cell mobilisation via actin regulation for TB-500. The pairing covers vascular and cellular-migration pathways.
Has this combination been characterised as a single formulation?
No. The combination has not been characterised as a single formulation. The rationale is based on complementary mechanisms described for each component individually in preclinical models.
Is this blend FDA approved?
No. Neither BPC-157 nor TB-500 is FDA approved for any indication. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human consumption.
How should this blend be stored?
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles. Both components maintain stability under standard peptide storage conditions.
What purity testing is performed?
Each component undergoes independent third-party testing including HPLC for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. A Certificate of Analysis is included with every order.
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.